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Abstract
Desmoplastic small round cell tumour is a rare malignant tumour with a male to female ratio of 4:1. It manifests
mostly at serosal sites. Here we present a case of a 28-year-old male patient, who presented with a fast growing
paratesticular mass. On biopsy nests and cords of small round cells, without a clear morphological lineage of
differentiation were seen. Occasionally desmoplatic small round cell tumour shows different lines of differentiation.
An unequivocal histological diagnosis might be difficult in such cases. Here we demonstrate by a combination of
methods the characteristic immunohistochemical profile and - albeit unusual - molecular background and discuss
the eventual link with Ewing sarcoma.
Immunohistochemical studies showed a membranous staining of Keratine AE1/3 and a dot-like staining of Desmine,
confirming its diagnosis. Using COBRA-FISH following a metaphase approach we demonstrated a balanced
translocation, t(11;22)(p13;q12) and in RT-PCR formation of the EWSR1-WT1 fusion product, a specific translocation of
desmoplastic round cell tumour. The fusion involves exon 9 of EWSR1 to exon 8 of WT1, an unusual fusion product,
though earlier described in a case of a desmoplastic small round cell tumour of the hand. The EWSR1-WT1 chimera
seems to function as an oncogenic transcription factor. Here the zinc finger domain of the WT1 acts with affinity with
certain promoter domains influencing the expression of various downstream proteins such as: PDGFA, PAX2, insulin-like
growth factor 1 receptor, epidermal growth factor receptor, IL2 receptor beta, BAIAP3, MLF1, TALLA-1, LRRC15 and ENT.
We discuss their potential oncogenic roles and potential therapeutic consequences.
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Introduction
Desmoplastic small round cell tumour (DSRT) was first
described as a distinct entity by Gerald and Rosai now
about 23 years ago [1]. The tumour is nowadays well-
characterized histologically and at the immunohisto-
chemical level and involves serosal surfaces. Microscopi-
cally, the morphologic prototype of the tumour shows
nests of small, round cells embedded within a desmo-
plastic stroma, giving it its descriptive name as an entity.
The cells show a multidirectional phenotype with
epithelial, myogenic and neural marker expression. The
tumour is located in the abdominal and pelvic peritoneal
cavity in the vast majority of cases. Extra-abdominal
sites are rare. Cases were described however in the cra-
nial cavity, lung, head and neck, salivary gland [2],
limbs, pancreas and paratesticular region. Although
most cases have been described in young men and chil-
dren, several cases have been described in older patients
[3-5] and in women, sometimes simulating ovarian
tumours [3,4,6], even with high CA125 levels [6,7].
DSRCT is associated with a distinct translocation which
shows a fusion between Ewing sarcoma gene (EWSR1)
and Wilms tumour gene (WT1). There are at least two
reports of hybrid tumours with features of both DSRCT
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[8] and one with an EWSR1-ERG fusion gene [6]. Rapid
growth and metastasis to liver, lungs, pleura, bone, spleen
and lymph nodes [9,3] is common. The reported prognosis
is poor, with a median survival of 17 months only [9-15].
At the meeting of the Connective Tissue Oncology
Society, November 2010, Subbiah et al presented data
from 161 patients, with a median survival duration of 2.4
years.
Long-term survivors are uncommon and therapeutical
possibilities are limited, although reports of debulking
combined with chemotherapy with high-dose multi-
agent alkylator-based systemic therapy mention response
rates and improved progression-free survival. A study of
Schwartz and co-workers [16] showed a progression-free
survival of 18% at five years, indicating a very poor
prognosis. Factors correlated with improved survival
i n c l u d eac o m p l e t eo rv e r yg o o dp a r t i a lr e s p o n s et o
therapy with the so-called P6 protocol; and a greater
than 90% tumour resection. The commonly used Mem-
orial Sloan-Kettering P6 protocol consists of four
courses of high-dose cyclophosphamide, doxorubicin,
and vincristine, interspersed with ifosfamide, etoposide,
and mesna in three cycles. In addition, some patients in
the literature underwent myeloablative chemotherapy
with stem cell rescue and/or radiation therapy. DSRCTs
are generally sensitive to chemotherapy and radiother-
apy, however their response is rarely lasting. Therefore,
surgical resection is considered to be of primary impor-
tance for achieving prolonged disease-free survival [16].
L a le ta l[ 1 4 ]s t u d i e d6 6p a t i e n t sa n df o u n dg r o s s
tumour resection significant in prolonging the overall
survival. In the case of resectable tumours the 3-year
survival was 58%, while in the case of non-resectable
tumour localizations the 3-year survival was 0%.
Livaditi et al. [15] found in a combination of radical
tumour excision with adjuvant chemotherapy, all had
recurrence within 2-6 months. Gil et al [12] observed
no correlation between the surgical excision and
improved survival rates.
In this report, we present a rare case of desmoplastic
round cell tumour presenting as a paratesticular mass
and with cytogenetic analysis using a multicolour Com-
bined Binary RAtio labelling Fluorescence In-situ Hybri-
dization (COBRA-FISH) method and with a rare
translocation variant detected by reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis of the t
(11;22) fusion gene product.
Materials and methods
Case report
A 32-year-old male presented in a referral hospital with
a distinct paratesticular scrotal mass, without other
complaints. On biopsy a diagnosis of desmoplastic small
round cell tumour was suggested. A subsequently per-
formed CT-scan showed extensive localization in the
abdomen.
Orchidectomy was performed. Subsequently, following
the diagnosis of DSRCT, the patient was treated with
chemotherapy: three cycles VIDE: Vincristine 1 mg/m
2,
Etoposide 150 mg/m
2, Doxorubicine 20 mg/m
2,I f o s f a -
mide 3000 mg/m
2. After three cycles chemotherapy, an
incomplete debulking procedure was performed and
post-operatively another three cycles VIDE were admi-
nistered. A complete resection was not possible, because
of tumour extension in the abdomen. The patient
returned back to work and was relatively well for one
and a half year. Unfortunately the patient died 24
months later with progressive metastases in the liver
and abdominal cavity.
Immunohistochemistry
Immunohistochemistry was performed on the biopsy as
well as on the debulking specimen using antibodies
directed against desmin (Dako, Glostrup, Denmark) and
CD99 (Dako), CD56 (Dako) and EMA (Dako) staining,
according to standard laboratory protocols.
Tumour sample and chromosome preparation
A fresh sample of tumour tissue was minced and subse-
quently inoculated into a culture flask containing 5 ml of
RPMI 1640 medium 1 mg/ml collagenase 1A (sigma-
Aldrich) and 1 mg/ml dispase (GIBCO) to enzymatically
disaggregate cells. After 16 hrs. of treatment, released
tumour cells were washed and cultured in RPMI 1640
medium, supplemented with 10% fetal calf serum and
penicillin/streptomycin. After five days of incubation,
metaphase cells were harvested using colcemid (20 ng/
ml) and incubated for two hrs. After trypsinization and
hypotonic treatment (0.075 M KCl for 12 min) cells were
fixed by three changed fixation steps using methanol/gla-
cial acetic acid (3:1 v/v). The cell suspension was dropped
and selected slides were used for COBRA-FISH analysis.
Molecular Cytogenetic Analysis
Slides with metaphase chromosomes were hybridized
using a multicolour FISH approach named COBRA-
FISH. A 48-colour FISH staining every chromosome-
arm in a different colour combination, digital imaging
and analysis were performed as previously described by
our group [17,18]. Hybridization with individual libraries
labelled with single fluorochromes was used to confirm
the detected rearrangements. Breakpoints were assigned
using inverted 4,6-diamidino-2-phenylindole (DAPI)
counterstained images of the chromosomes. Karyotypes
have been described according to the International Sys-
tem for Human Cytogenetic Nomenclature (ISCN),
2009.
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RNA isolation, reverse transcription, PCR and gel elec-
trophoresis were performed as described earlier. RNA
was extracted from fresh frozen tumour tissue with TRI-
zol (Gibco BRL Life Technologies, Gaithersburg, MD,
USA). RNA was reversely transcribed in a mix contain-
ing 2 μgR N Aa n d0 . 2μl AMV-reverse transcriptase
(Boehringer Mannheim, Germany). Amplification by
PCR was carried out using 1 U Ampli-Taq polymerase
(Perkin-Elmer Thermal cycler. A total of 30 cycles were
performed of 30 sec at 94°C (denaturation), 60 sec at
68°C (annealing) and 60 sec at 72°C (elongation). An
assay that uses a forward EWSR1 primer (5’ EWSR1:
EWS-ex7 for 5’-TGTAAAACGACGGCCAGTtcctacagc-
caagctccaagtc-3’)a n dar e v e r s eW T 1p r i m e r( 3 ’ WT1:
WT1-ex9rev 5’-CAGGAAACAGCTATGACCgaccagga-
gaactttcgctgac-3’), was performed to detect EWSR1/
WT1 chimerical transcripts.
Results
Histopathology
Sections obtained from the testicular tumour mass (Fig-
ure 1A) were composed of sharply defined nests, sheets
and cords of undifferentiated cells (Figure 1B and 1C)
tumour cells have scant cytoplasm, indistinct cell bor-
ders and round to oval nuclei. Mitotic figures were
n u m e r o u s ,u pt of i v ep e rh i g hp o w e rf i e l d .A p o p t o s i s
and necrosis were prominent. Extensive desmoplastic
stroma was present.
Immunohistochemistry
Desmin immunohistochemistry showed a positive stain-
ing in a paranuclear dot-like fashion (Figure 1D), while
CD56 and EMA showed a diffuse membranous staining
and CD99 a faint membranous staining.
Molecular Cytogenetic Analysis
Multicolour FISH-based karyotyping is capable of show-
ing each individual arm of every chromosome. A repre-
sentative karyotype imagei ss h o w ni nF i g u r e2 .T h e
following karyotype was ascertained: 46, XY, t(11;22)
(p13;q12), no secondary chromosomal alteration were
detected.
RT-PCR
Detection of the EWSR1-WT1 fusion transcript by RT-
PCR showed a fusion product in the expected range.
The sequence analysis showed a fusion product of exon
9 EWSR1 with exon 8 of WT1.
Discussion
Desmoplastic small round cell tumour (DSCRT) is a rare
malignant tumour, sometimes with a distinct histological
appearance and less frequently with different growth pat-
terns. A pure morphological diagnosis is sometimes diffi-
cult and molecular techniques can be helpful to
differentiate between other poorly differentiated tumours.
The typical presentation is with a paraserosal mass and a
predilection for serosal surfaces, mainly the peritoneum
and - as in our case - the paratesticular region. DSCRT
shows a histological pattern with small cells growing in a
nested pattern with abundant, desmoplastic stroma [4,5].
Several atypical patterns have been described with rhab-
doid, clear cell, pleomorphic, glandular, basaloid patterns,
solid areas with little stroma, pseudorosettes, fusiform and
papillary areas [4,19-21].
Figure 1 Macro- and microscopic features. A: gross specimen. The tumour masses were solid, firm, with grey-white cut surfaces and areas of
necrosis. B: light micrograph showing compact nests and sheets of small, round cells in desmoplastic stroma. Magnification 25× C: numerous
mitotic figures can be observed. Magnification 200× D: Immunohistochemical detection of desmin; the reaction shows a typical paranuclear dot-
like staining. Magnification 200×.
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the co-expression of epithelial, mesenchymal and neural
markers (table 1). Gerald et al. [4] suggested that
DSRCT is a primitive tumour related to mesothelium,
because of the prevalence in serosal cavities. The
tumour growth pattern mimics that of mesothelioma.
Fetal mesothelium co-expresses Keratin and Desmin.
Frequent WT1 expression has been reported in
mesothelioma. Calretinin, a protein highly expressed in
normal mesothelium as well as in mesothelioma, is cur-
iously negative however in DSRCT [22].
At the genomic level, it is not entirely clear whether
the EWSR1-WT1 translocation is a specific
translocation for DSRCT or not. Alaggio et al. described
two pediatric cases with morphological, and immunohis-
tochemical features of leiomyosarcomas with a EWSR1-
WT1 translocation. Surprisingly, the behaviour of these
tumours seemed to have a favourable course. The pre-
sence of this translocation in leiomyosarcomas suggests
that the fusion of EWSR1-WT1 is not entirely specific
for DSRCT [23]. Wang et al. described 4 children with
renal tumours with EWSR1-WT1 fusion and typical his-
tological and immunohistochemical features of DSRCT,
but without the desmoplastic stroma. Curiously, the
patients in this study have a much lower age of presen-
tation than the average and their prognosis seems to be
better than usually described for DSRCT’s [24].
At genomic level, DSRCT is associated with a recur-
rent chromosomal translocation, t(11;22)(p13;q12) form-
ing an in-frame chimera transcript. At the protein level
a fusion of the amino-terminal domain (NTD) of the
EWSR1 gene and three of the four carboxyl-terminal
zinc fingers of the WT1 tumour suppressor gene takes
place [19]. A specific chromosomal translocation, t
(11;22)(p12;q12), has been identified in DSRCT in 93%
of all cases [25]. The diagnostic dilemma in those cases
is between the phenotype and the genotype. There are
at least two reports of hybrid tumours with features of
both DSRCT and Ewing sarcoma, one with a EWSR1-
FLI1 fusion gene [8] and one with a EWSR1-ERG fusion
gene [6]. Their classification is therefore enigmatic. As
Figure 2 COBRA-FISH karyogram of the case showing the
characteristic t(11;22)(p13;q12) as a solely alteration.
Rearranged chromosomes are indicated by arrowheads.
Table 1 Antibody profiles in the literature
Antibody Gerald, Ordonez and Lae (*) Zhang et al. [22]
Desmin 135/149 90.6% 21/23 91%
Vimentin 86/93 92.5% NT
NSE 105/131 80.2% NT
WT1 62/68 91.2% 16/23 70%
Keratin (not specified) 132/149 88.6% NT
CAM5.2 NT 21/23 91%
kerAE1AE3 NT 16/23 70%
EMA 74/79 93.7% NT
CD99 NT 13/23 57%
Muscle specific actin 2/89 2.2% NT
S-100 6/30 20% NT
Synaptophysin 3/19 15.8% NT
Chromogranin 2/68 2.9% NT
PLAP NT 17/21 81%
Myoglobine NT 5/17 29%
Myogenine 0/18 0% 0/22 0%
Calretinine NT 4/21 19%
HER2 NT 7/18 39%
c-kit NT 2/14 14%
(*) literature data are retrieved from Gerald et al [36], Ordonez [21] and Lae et al. [25]. Desmin and vimentin show a typical paranuclear dotlike staining. The
target genes (PDGF-A, PDGFR beta en TGF-beta3) are almost all positive. NT: Not Tested
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EWSR1 N-terminal domain and the SP3 zinc finger
DNA-binding domain but not the inhibitory domain of
SP3-domain of WT1. The first zinc finger protein
involved, also acts as a transcriptional activator of
repressor. There are a number of similarities between
both tumours: the age of presentation is similar and his-
tologically both tumours show small, undifferentiated
round cells. The immunophenotype is however different.
In the case of ES/PNET usually a restricted or unidirec-
tional differentiation toward neural elements is seen,
whereas DSRCT shows a divergent differentiation.
There is a large overlap: both Keratin and occasionally
Desmin can be expressed in ES/PNET. Conversely,
CD99 expression is also found in DSRCT, as in our
case. This phenomenon emphasizes the importance of
molecular research to distinquish the different tumors,
especially because of the more distinguish therapies [26].
The classical fusion in DSCRT is EWSR1 exon 7/WT1
exon 8. Translocation variants of EWSR1-WT1, in
decreasing reported frequencies are: three cases with a
EWSR1 exon 9-WT1 exon 8, two cases with a EWSR1
exon 10-WT1 exon 8, one case with a EWSR1 exon 7-
WT exon 8 [27], one case with a EWSR1 exon 5 -WT1
exon 10 [24] and one case with EWSR1 exon 9-WT1
exon 8 [28]. In all cases the junctions produced in-
frame transcripts. The case presented here shows a rare
fusion between EWSR1 exon 9- WT1 exon 8, similar to
that reported by Adsay et al of a DSCRT of the hand.
The translocation breakpoint within the EWSR1 gene
occurs in intron 9 retaining of the amino-terminal
domain (NTD) of EWSR1 that fuses zinc fingers 2-4 to
the NTD of WT1. WT1 is a zinc-finger protein, with
specific DNA- and RNA-binding domains. The translo-
cation event in DSRCT abolishes the RNA-binding
activity of EWSR1, as well as the transcriptional
Table 2 Clinical trials
NCT ID Drugs
00417807 Imatinib mesylate
01189643 Iriontecan, temozolomide, bevacizumab incorporated into an existing schedule of high dose alkylator.
00563680 AMG-479
00055952 Exatecan mesylate
01277744 Hyperthermic peritoneal perfusion with cisplatin.
01099644 Radioimmunotherapy.
00062205 Imatinib mesylate
00436657 Hyperthermic perfusion with cisplatin.
01287104 NK cell infusion following allogeneic stem cell transplantation.
01125449 Ascorbic acid (vitamin C)
00445965 Iodine I131 monoclonal antibody 3F8.
00720174 IMC-A12, doxorubicine hydrochloride.
00003926 Amifostine to protect form side effects of PSCT.
00002515 Chemotherapy in combination with bone marrow transplantation.
00024258 Arsenic trioxide.
00043979 Stem cell transplantation.
00562380 AMG-479.
01154452 GDC-0449 and RO4929097.
00025441 Combination chemotherapy.
00794521 Pazopanib.
00474994 Sunitinib malate
00526149 BI 2536
00002466 Combination chemotherapy and radiation therapy.
00030667 Imatinib mesylate.
00089245 Iodine I131 monoclonal antibody 8H9.
00093821 Tanespimycin
00662233 Combination chemotherapy
00002898 Surgery followed by chemotherapy.
01189253 Doxorubicin or Trabectedin.
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that WT1 binds to specific cis-elements in the IGF-IR
gene regulatory region and suppresses IGF-IR gene
transcription.
The fusion proteins are believed to function as strong
transcription factors, with direct targets PDGFA, Pax2,
insulin-like growth factor 1 receptor (IGF-IR), epidermal
growth factor receptor, IL2 receptor beta, BAIAP3,
MLF1, TALLA-1, and LRRC15 [29-32].
IGF-IR is a potent anti-apoptotic receptor tyrosine
kinase [25]. IL2 receptor beta is promoted by the isoform
EWSR1-WT1 (-KTS), whereas the desmoplastic stroma
expresses IL2 and IL15, so functions as a paracrine growth
signal [31,32]. BAIAP3, this protein is believed to partici-
pate in regulated exocytosis and expressed in tumour cells
of DSRCT and enhance tumour growth by secretion of
autocrine or paracrine growth factors [33]. MLF1 is
induced approximately eight-fold by EWSR1-WT1 (-KTS)
and plays a role in proliferation and cell survival [30].
TALLA1 induction regulates interactions with extracellu-
lar matrix, migration, and invasion. LRRC15 by EWSR1-
WT1 (+KTS) is strongly expressed in invasive breast can-
cer cell line and possibly contributes to the invasive phe-
notype of DSCRT [34]. Some of these genes might serve
as target for therapy, especially when novel treatment
modalities are investigated [35]. Different strategies for
therapy are summarized in table 2, with chemotherapy,
radiotherapy, stem cell transplantation and with antibodies
for example against the insulin-like growth factor 1 recep-
tor (AMG 479).
In conclusion, here we report a detailed molecular
characterization of DSCRT with a rare translocation var-
iant forming a junction between the EWSR1 exon 9 and
WT1 exon 8 at the transcript level. The functional con-
s e q u e n c e so ft h i sv a r i a n ti nt e r m so fd y s r e g u l a t i o na t
the target gene level, with potential implication of novel
treatment modalities, need additional investigation.
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